Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial

Astrid Lipplaa, Judith R Kroep, Lizz van der Heijden, Paul C Jutte, Pancras C W Hogendoorn, Sander Dijkstra, Hans Gelderblom, Astrid Lipplaa, Judith R Kroep, Lizz van der Heijden, Paul C Jutte, Pancras C W Hogendoorn, Sander Dijkstra, Hans Gelderblom

Abstract

Lessons learned: Adjuvant treatment with zoledronic acid did not decrease the recurrence rate of giant cell tumor of bone (GCTB) in this study. The efficacy could not be determined because of the small sample size.GCTB recurrences, even in the denosumab era, are still an issue; therefore, a randomized study exploring the efficacy of zoledronic acid in the adjuvant setting in GCTB is still valid.

Background: Bisphosphonates are assumed to inhibit giant cell tumor of bone (GCTB)-associated osteoclast activity and have an apoptotic effect on the neoplastic mononuclear cell population. The primary objective of this study was to determine the 2-year recurrence rate of high-risk GCTB after adjuvant zoledronic acid versus standard care.

Methods: In this multicenter randomized open-label phase II trial, patients with high-risk GCTB were included (December 2008 to October 2013). Recruitment was stopped because of low accrual after the introduction of denosumab. In the intervention group, patients received adjuvant zoledronic acid (4 mg) intravenously at 1, 2, 3, 6, 9, and 12 months after surgery.

Results: Fourteen patients were included (intervention n = 8, controls n = 6). Median follow-up was long: 93.5 months (range, 48-111). Overall 2-year recurrence rate was 38% (3/8) in the intervention versus 17% (1/6) in the control group (p = .58). All recurrences were seen within the first 15 months after surgery.

Conclusion: Adjuvant treatment with zoledronic acid did not decrease the recurrence rate of GCTB in this study. The efficacy could not be determined because of the small sample size. Because recurrences, even in the denosumab era, are still an issue, a randomized study exploring the efficacy of zoledronic acid in the adjuvant setting in GCTB is still valid.

Trial registration: ClinicalTrials.gov NCT00889590.

© AlphaMed Press; the data published online to support this summary are the property of the authors.

Figures

Figure 1.
Figure 1.
Relapse free survival, Kaplan Meier.

References

    1. Athanasou N, Bansal M, Forsyth R et al. Giant cell tumour of bone In: Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F, eds. WHO Classification of Tumours in Soft Tissue and Bone. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC), 2013.
    1. Liede A, Bach BA, Stryker S et al. Regional variation and challenges in estimating the incidence of giant cell tumor of bone. J Bone Joint Surg Am 2014;96:1999–2007.
    1. Forsyth RG, De Boeck G, Baelde JJ et al. CD33+ CD14‐ phenotype is characteristic of multinuclear osteoclast‐like cells in giant cell tumor of bone. J Bone Miner Res 2009;24:70–77.
    1. Branstetter DG, Nelson SD, Manivel JC et al. Denosumab induces tumor reduction and bone formation in patients with giant‐cell tumor of bone. Clin Cancer Res 2012;18:4415–4424.
    1. Atkins GJ, Kostakis P, Vincent C et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006;21:1339–1349.
    1. Lindeman JH, Hanemaaijer R, Mulder A et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004;165:593–600.
    1. Maggiani F, Forsyth R, Hogendoorn PC et al. The immunophenotype of osteoclasts and macrophage polykaryons. J Clin Pathol 2011;64:701–705.
    1. Arbeitsgemeinschaft K, Becker WT, Dohle J et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008;90:1060–1067.
    1. Algawahmed H, Turcotte R, Farrokhyar F et al. High‐speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: A systematic review and meta‐analysis. Sarcoma 2010;2010:586090.
    1. Balke M, Schremper L, Gebert C et al. Giant cell tumor of bone: Treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008;134:969–978.
    1. Kivioja AH, Blomqvist C, Hietaniemi K et al. Cement is recommended in intralesional surgery of giant cell tumors: A Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008;79:86–93.
    1. van der Heijden L, Dijkstra PD, van de Sande MA et al. The clinical approach toward giant cell tumor of bone. The Oncologist 2014;19:550–561.
    1. van der Heijden L, van de Sande MA, Dijkstra PD. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant‐cell tumor of the long bones. Acta Orthop 2012;83:401–405.
    1. Klenke FM, Wenger DE, Inwards CY et al. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011;469:591–599.
    1. Neville‐Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010;46:1211–1222.
    1. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584–593.
    1. Lau CP, Huang L, Wong KC et al. Comparison of the anti‐tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone. Connect Tissue Res 2013;54:439–449.
    1. Lau CP, Wong KC, Huang L et al. A mouse model of luciferase‐transfected stromal cells of giant cell tumor of bone. Connect Tissue Res 2015;56:493–503.
    1. Cheng YY, Huang L, Lee KM et al. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004;75:71–77.
    1. Yang T, Zheng XF, Li M et al. Stimulation of osteogenic differentiation in stromal cells of giant cell tumour of bone by zoledronic acid. Asian Pac J Cancer Prev 2013;14:5379–5383.
    1. Chang SS, Suratwala SJ, Jung KM et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res 2004:103–109.
    1. Balke M, Neumann A, Szuhai K et al. A short‐term in vivo model for giant cell tumor of bone. BMC Cancer 2011;11:241.
    1. Arpornchayanon O, Leerapun T. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: A case report and review of the literature. J Med Assoc Thai 2008;91:1609–1612.
    1. Chaudhary P, Khadim H, Gajra A et al. Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor. Onkologie 2011;34:702–704.
    1. Gille O, Oliveira Bde A, Guerin P et al. Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy. Spine (Phila Pa 1976) 2012;37:E396–E399.
    1. Zhang W, Zhang Y, Li P et al. Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine. Spine (Phila Pa 1976) 2011;36:E1166–E1172.
    1. Fujimoto N, Nakagawa K, Seichi A et al. A new bisphosphonate treatment option for giant cell tumors. Oncol Rep 2001;8:643–647.
    1. Tse LF, Wong KC, Kumta SM et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case‐control study. Bone 2008;42:68–73.
    1. Xu W, Wang Y, Wang J et al. Long‐term administration of bisphosphonate to reduce local recurrence of sacral giant cell tumor after nerve‐sparing surgery. J Neurosurg Spine 2017;26:716–721.
    1. Balke M, Campanacci L, Gebert C et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010;10:462.
    1. O'Donnell RJ, Springfield DS, Motwani HK et al. Recurrence of giant‐cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994;76:1827–1833.
    1. Yu X, Xu M, Xu S et al. Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates. Oncol Lett 2013;5:447–451.
    1. Gouin F, Rochwerger AR, Di Marco A et al. Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. Eur J Cancer 2014;50:2425–2431.
    1. Kundu ZS, Sen R, Dhiman A et al. Effect of intravenous zoledronic acid on histopathology and recurrence after extended curettage in giant cell tumors of bone: A comparative prospective study. Indian J Orthop 2018;52:45–50.
    1. Cornelis F, Truchetet ME, Amoretti N et al. Bisphosphonate therapy for unresectable symptomatic benign bone tumors: A long‐term prospective study of tolerance and efficacy. Bone 2014;58:11–16.
    1. Chen KH, Wu PK, Chen CF. Zoledronic acid‐loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage. Eur Spine J 2015;24:2182–2188.
    1. Nishisho T, Hanaoka N, Miyagi R et al. Local administration of zoledronic acid for giant cell tumor of bone. Orthopedics 2015;38:e25–e30.
    1. Thomas D, Henshaw R, Skubitz K et al. Denosumab in patients with giant‐cell tumour of bone: An open‐label, phase 2 study. Lancet Oncol 2010;11:275–280.
    1. Chawla S, Henshaw R, Seeger L et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open‐label, parallel‐group, phase 2 study. Lancet Oncol 2013;14:901–908.
    1. Gaston CL, Grimer RJ, Parry M et al. Current status and unanswered questions on the use of denosumab in giant cell tumor of bone. Clin Sarcoma Res 2016;6:15.
    1. Ueda T, Morioka H, Nishida Y et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: A multicenter phase II trial. Ann Oncol 2015;26:2149–2154.
    1. Rutkowski P, Ferrari S, Grimer RJ et al. Surgical downstaging in an open‐label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 2015;22:2860–2868.
    1. Errani C, Ruggieri P, Asenzio MA et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010;36:1–7.
    1. Mak IW, Evaniew N, Popovic S et al. A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 2014;96:e127.
    1. Shibuya I, Takami M, Miyamoto A et al. In vitro study of the effects of denosumab on giant cell tumor of bone: Comparison with zoledronic acid. Pathol Oncol Res 2019;25:409–419.
    1. van der Heijden L, van de Sande MA, Hogendoorn PC et al. Neoadjuvant denosumab for extensive giant cell tumor in os ischium: A case report. Acta Orthop 2015;86:393–395.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner